A cikin gwaji na 3 na baya-bayan nan, Tirzepatide ya nuna sakamako mai ƙarfafawa a cikin jiyya na nau'in ciwon sukari na 2.An gano magungunan don rage yawan matakan sukari na jini da kuma inganta asarar nauyi a cikin marasa lafiya da cutar.
Tirzepatide allura ce ta mako-mako wacce ke aiki ta hanyar niyya ga glucagon-kamar peptide-1 (GLP-1) da masu karɓar insulinotropic polypeptide (GIP) masu dogaro da glucose.Waɗannan masu karɓa suna taka muhimmiyar rawa wajen daidaita matakan sukari na jini da haɓaka samar da insulin.
Gwajin, wanda Eli Lilly da Kamfanin ke gudanarwa, ya yi rajista fiye da mutane 1,800 da ke da nau'in ciwon sukari na 2 waɗanda ba sa shan insulin ko ɗaukar tsayayyen adadin insulin.An ba wa mahalarta damar ba da izini don karɓar allurar Tirzepatide na mako-mako ko placebo.
A ƙarshen gwaji na makonni 40, masu bincike sun gano cewa marasa lafiya da suka karbi Tirzepatide sun rage yawan matakan jini fiye da wadanda suka karbi placebo.A matsakaita, mahalarta da aka yi amfani da su tare da Tirzepatide sun sami raguwar kashi 2.5 a cikin matakan haemoglobin A1c (HbA1c), idan aka kwatanta da raguwar kashi 1.1 a cikin rukunin placebo.
Bugu da ƙari, marasa lafiya da ke karɓar Tirzepatide suma sun sami babban asarar nauyi.A matsakaita, sun rasa kashi 11.3 na nauyin jikinsu, idan aka kwatanta da kashi 1.8 na rukunin placebo.
Sakamakon gwajin yana da mahimmanci musamman idan aka yi la'akari da karuwar yaduwar ciwon sukari na 2 a duniya.A cewar Hukumar Lafiya ta Duniya, yawan manya da ke fama da ciwon sukari ya ninka sau hudu tun daga shekarar 1980, inda aka kiyasta kimanin manya miliyan 422 ne suka kamu da cutar a shekarar 2014.
"Sarrafa nau'in ciwon sukari na 2 na iya zama kalubale ga mutane da yawa, kuma ana maraba da sabbin hanyoyin magance cutar," in ji Dokta Juan Frias, babban mai bincike kan binciken."Sakamakon wannan binciken ya nuna cewa Tirzepatide na iya ba da sabon zaɓi mai ban sha'awa ga marasa lafiya da nau'in ciwon sukari na 2 waɗanda ke ƙoƙarin sarrafa matakan sukari na jini."
Ko da yake ana buƙatar ƙarin nazarin don tantance amincin dogon lokaci da ingancin Tirzepatide, sakamakon ƙarfafawa na miyagun ƙwayoyi a cikin wannan gwaji na 3 alama ce mai kyau ga mutanen da ke da ciwon sukari na 2.Idan hukumomin gudanarwa sun amince da su, Tirzepatide na iya samar da sabon zaɓin magani mai inganci don sarrafa cutar da inganta rayuwar marasa lafiya.
Lokacin aikawa: Juni-03-2023